LPL Financial LLC Grows Position in Abrdn Life Sciences Investors (NYSE:HQL)

LPL Financial LLC boosted its position in Abrdn Life Sciences Investors (NYSE:HQL - Free Report) by 82.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 287,095 shares of the company's stock after acquiring an additional 129,313 shares during the period. LPL Financial LLC owned 1.05% of Abrdn Life Sciences Investors worth $3,767,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Absolute Investment Advisers LLC purchased a new position in shares of Abrdn Life Sciences Investors during the fourth quarter valued at approximately $5,242,000. Sanctuary Advisors LLC boosted its holdings in Abrdn Life Sciences Investors by 11.4% during the 3rd quarter. Sanctuary Advisors LLC now owns 13,256 shares of the company's stock worth $183,000 after acquiring an additional 1,355 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Abrdn Life Sciences Investors in the fourth quarter valued at about $3,129,000. Wolverine Asset Management LLC bought a new position in shares of Abrdn Life Sciences Investors during the fourth quarter valued at about $1,594,000. Finally, Commonwealth Equity Services LLC boosted its holdings in Abrdn Life Sciences Investors by 3.2% during the fourth quarter. Commonwealth Equity Services LLC now owns 30,119 shares of the company's stock worth $395,000 after purchasing an additional 933 shares during the last quarter. Institutional investors own 32.21% of the company's stock.

Abrdn Life Sciences Investors Price Performance

Shares of NYSE HQL traded down $0.11 during midday trading on Wednesday, reaching $11.66. The company's stock had a trading volume of 11,877 shares, compared to its average volume of 132,366. The firm has a 50 day moving average price of $12.91 and a 200-day moving average price of $13.76. Abrdn Life Sciences Investors has a 12-month low of $10.55 and a 12-month high of $15.90.

Abrdn Life Sciences Investors Cuts Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, March 31st. Stockholders of record on Friday, February 21st were given a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a dividend yield of 16.13%. The ex-dividend date was Friday, February 21st.

Insider Transactions at Abrdn Life Sciences Investors

In related news, major shareholder Saba Capital Management, L.P. sold 15,143 shares of the company's stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $14.27, for a total value of $216,090.61. Following the transaction, the insider now directly owns 3,381,371 shares in the company, valued at approximately $48,252,164.17. This represents a 0.45 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last ninety days, insiders have sold 271,478 shares of company stock valued at $3,504,316. 10.06% of the stock is currently owned by corporate insiders.

Abrdn Life Sciences Investors Company Profile

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.